Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HSA-rhGH in children with growth disorders caused by endogenous growth hormone deficiency
CTR20213096Phase 2Active
- Sponsor
- Zhejiang Unicon Bioengineering
- Start
- Aug 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of albusomatropin in growth hormone deficiency (GHD), sponsored by Zhejiang Unicon Bioengineering. Started Aug 2022; status: active.
02
Drugs
albusomatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on CTR20213096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213096.